The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) drugs in development market research report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued products.
GlobalData tracks 140 drugs in development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by 109 companies/universities/institutes. The top development phase for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) is phase ii with 54 drugs in that stage. The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline has 122 drugs in development by companies and 18 by universities/ institutes. Some of the companies in the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline products market are: Bristol-Myers Squibb, Merck and Pfizer.
The key targets in the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline products market include Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, and Programmed Cell Death 1 Ligand 1.
The key mechanisms of action in the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline product include Programmed Cell Death Protein 1 Antagonist with 23 drugs in Phase III. The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline products include 13 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline products market including Monoclonal Antibody, and Small Molecule.
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) overview
Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the Epstein-Barr virus (EBV) or HIV increase risk compared to the general population. Treatment includes surgery, radiation therapy, and chemotherapy.
For a complete picture of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
